RNRMarketResearch.com

Worldwide Drug Delivery Technologies Market 2017 Forecast, Trends & Company Profiles

Press Release   •   Sep 17, 2014 06:04 EDT

Analysis and discussion about drug delivery technologies market, its forecasts and more is now available in the global research report “Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017”. This report is of 316 pages and can be ordered at ReportsnReports.com.

The global drug delivery market was worth $142.5 billion in the year 2012. Patent expiries of certain blockbuster drugs, growing demand for self administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer, growing focus on pediatric and geriatric patients, and advancing technology are accelerating the growth of this market. However, drug failures and recalls, and technical barriers will hamper the growth of this market, to a certain extent.

The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery; the market is forecast till 2017. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.

Strategic collaborations, self administration and home care drug delivery devices, and expanding applications of drug delivery into niche therapeutic areas represent vast opportunities for key players in this market. The growing number of elderly persons is a large consumer of home care drug delivery devices. The global ageing population (above 60 years) is set to increase from 784 million in 2011 to 2 billion by 2050 and 2.8 billion by 2100. (Source: UN Population Division). An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use drug delivery systems.

Complete report available at http://www.reportsnreports.com/reports/237071-drug-delivery-technologies-market-metered-dose-inhalers-needle-free-injectors-auto-injectors-nasal-sprays-transdermal-patches-nebulizers-infusion-pumps-drug-eluting-stents-sustained-release-ocular-implants-global-forecasts-to-2017.html .

Striking right partnership deal and enhancing the bioavailability of drugs are some of the burning issues in this market. In spite of a large number of strategic collaborations taking place every year, pharmaceutical and biotechnology companies are facing problems in finding a right drug delivery partner. Considering this need, a number of national and international conferences are organized by various associations and organizations to facilitate drug delivery partnerships.

The geographies covered in this study are North America, Europe, Asia and Rest of the world (RoW). North America is the largest market for drug delivery, followed by Europe and Asia. North America and Europe are expected to grow at a slower pace, primarily due to a certain amount of saturation in the market. The Asian market is poised to register maximum growth over the next five years, owing to the expansion of Asian economy, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.

Scope of the Report

This research report categorizes the global drug delivery technology market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the drug delivery market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Inquire for discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=237071 . (Original Price US $4650 for single user)


List of Figures

Figure 1 Global Drug Delivery Market, By Route Of Administration (2012)

Figure 2 Drug Delivery Market, By Geography, 2010 – 2017 ($Billion)

Figure 3 Global Drug Delivery Market Segmentation

Figure 4 Market Dynamics

Figure 5 Porter’s Five Forces Analysis For Drug Delivery Market

Figure 6 Value Chain Analysis

Figure 7 Global Pulmonary Drug Delivery: Market Share Analysis,By Key Player, 2012

Figure 8 Global Transdermal Drug Delivery: Market Share Analysis, By Key Player, 2012

Figure 9 Global Conventional Injection Devices: Market Share Analysis, By Key Player, 2012

Figure 10 Global Self-Injection Devices: Market Share Analysis,By Key Player, 2012

Figure 11 Global Implantable Drug Delivery: Market Share Analysis,By Key Player, 2012

Figure 12 Opportunity Matrix: Global Drug Delivery Market (2012)

Figure 13 Oral Drug Delivery Market Share (2012)

Figure 14 Key Growth Strategies, 2010 – 2013

Figure 15 3m Company: Total Revenue And R&D Expenses,2009 – 2011 ($Million)

Figure 16 Alkermes: Total Revenue And R&D Expenditure,2009 – 2011 ($Million)

Figure 17 Aptalis Pharma, Inc.: Total Revenue And R&D Expenses,2009 – 2011 ($Million)

Figure 18 Baxter International: Total Revenue And R&D Expenses,2010 – 2012 ($Million)

Figure 19 Becton, Dickinson: Total Revenue And R&D Expenditure,2010 – 2012 ($Million)

Figure 20 Catalent Pharma Solutions: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)

Figure 21 Teva Pharmaceutical Industries Limited: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)

Figure 22 Endo Health Solutions, Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)

Figure 23 Johnson & Johnson, Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)

Figure 24 Nektar Therapeutics, Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)

Figure 25 Psivida Corporation: Total Revenue, 2009 – 2011 ($Million)

Figure 26 Skyepharma Plc: Total Revenue And R&D Expenses,2009 – 2011 ($Million)

Figure 27 The Dow Chemical Company: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)

Figure 28 Valeant Pharmaceuticals: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)

Figure 29 Ypsomed: Total Revenue And R&D Expenses,2009 – 2011 ($Million)

Purchase a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=237071 . (This is a premium research report priced at US$ 4650 for single user PDF license).


About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. Our research specialists & industry experts, through our market research offerings, ensure we deliver on all your business & industry research requirements - first time and every time!